NO20062948L - Promotere for ekspresjon i modifisert vaccinia-virus Ankara - Google Patents

Promotere for ekspresjon i modifisert vaccinia-virus Ankara

Info

Publication number
NO20062948L
NO20062948L NO20062948A NO20062948A NO20062948L NO 20062948 L NO20062948 L NO 20062948L NO 20062948 A NO20062948 A NO 20062948A NO 20062948 A NO20062948 A NO 20062948A NO 20062948 L NO20062948 L NO 20062948L
Authority
NO
Norway
Prior art keywords
expression
vaccinia virus
promote
modified vaccinia
virus ankara
Prior art date
Application number
NO20062948A
Other languages
English (en)
Inventor
Sonja Leyrer
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Publication of NO20062948L publication Critical patent/NO20062948L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse gjelder promotere, fortrinnsvis for ekspresjon av gener og/eller kodende sekvenser i vaccinia-virus, feks. modifisert vaccinia-virus Ankara (MVA). Oppfinnelsen gjelder videre ekspresjonskassetter som omfatter slike promotere, vektorer som omfatter ekspresjonskassettene, samt farmasøytiske preparater og vaksiner.
NO20062948A 2003-11-24 2006-06-23 Promotere for ekspresjon i modifisert vaccinia-virus Ankara NO20062948L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301730 2003-11-24
EP04000943A EP1536015B1 (en) 2003-11-24 2004-01-17 Promoters for expression in modified vaccinia virus ankara
PCT/EP2004/012125 WO2005054484A1 (en) 2003-11-24 2004-10-27 Promoters for expression in modified vaccinia virus ankara

Publications (1)

Publication Number Publication Date
NO20062948L true NO20062948L (no) 2006-08-23

Family

ID=34442836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062948A NO20062948L (no) 2003-11-24 2006-06-23 Promotere for ekspresjon i modifisert vaccinia-virus Ankara

Country Status (18)

Country Link
US (3) US7816508B2 (no)
EP (4) EP1536015B1 (no)
JP (2) JP2007512009A (no)
KR (1) KR20060109873A (no)
CN (1) CN1898390A (no)
AT (4) ATE377088T1 (no)
AU (1) AU2004295382A1 (no)
BR (1) BRPI0416916A (no)
CA (1) CA2546680A1 (no)
DE (4) DE602004009743T2 (no)
DK (3) DK1845164T3 (no)
EA (1) EA012846B1 (no)
IL (4) IL174653A0 (no)
NO (1) NO20062948L (no)
NZ (1) NZ547405A (no)
SG (2) SG169325A1 (no)
UA (1) UA90098C2 (no)
WO (1) WO2005054484A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
EP2042604A1 (en) * 2007-09-26 2009-04-01 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) VV promoter driven overexpression of recombinant antigens
CA2741724C (en) * 2008-11-27 2016-10-04 Bavarian Nordic A/S Promoters for recombinant viral expression
US8613936B2 (en) 2009-03-13 2013-12-24 Bavarian Nordic A/S Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106754921A (zh) * 2016-12-12 2017-05-31 孙浩 哺乳动物细胞表达启动子及其制造和使用方法
CN111107872A (zh) * 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN121443308A (zh) 2023-03-17 2026-01-30 亥姆霍兹慕尼黑中心-德国健康与环境研究中心(有限公司) 用于治疗乙型肝炎的hbv抗原制剂
WO2025172435A1 (en) 2024-02-13 2025-08-21 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Hbv antigen formulation for treating hepatitis b
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
FR3171450A1 (fr) 2025-01-17 2026-07-24 Odimma Therapeutics Virus enveloppé pour la transfection d’acides nucléiques exogènes.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
KR100880765B1 (ko) 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
CN100446812C (zh) * 2001-03-08 2008-12-31 美国国有健康与人类服务部 表达修饰的hiv包膜、gag和pol基因的mva
ES2256747T3 (es) 2002-05-16 2006-07-16 Bavarian Nordic A/S Expresion de genes en el virus de la vacuna modificado, usando el promotor ati de la viruela de la vaca.
WO2004015118A1 (en) * 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
DE602004009743T2 (de) * 2003-11-24 2008-08-28 Bavarian Nordic A/S Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara

Also Published As

Publication number Publication date
ATE420191T1 (de) 2009-01-15
IL174653A0 (en) 2006-08-20
US20110008792A1 (en) 2011-01-13
SG142300A1 (en) 2008-05-28
EP1956094B1 (en) 2011-04-06
EP1845164A3 (en) 2008-03-19
IL199127A (en) 2010-12-30
EP1845164B1 (en) 2010-06-16
US20080112971A1 (en) 2008-05-15
UA90098C2 (en) 2010-04-12
BRPI0416916A (pt) 2007-01-23
DE602004027767D1 (de) 2010-07-29
EP1689872A1 (en) 2006-08-16
KR20060109873A (ko) 2006-10-23
EP1845164A2 (en) 2007-10-17
DE602004009743D1 (de) 2007-12-13
DK1536015T3 (da) 2008-02-18
CN1898390A (zh) 2007-01-17
CA2546680A1 (en) 2005-06-16
ATE377088T1 (de) 2007-11-15
DE602004032187D1 (de) 2011-05-19
EP1956094A1 (en) 2008-08-13
IL199128A (en) 2011-03-31
EP1536015A1 (en) 2005-06-01
ATE471383T1 (de) 2010-07-15
WO2005054484A1 (en) 2005-06-16
DE602004018975D1 (de) 2009-02-26
EP1536015B1 (en) 2007-10-31
US20110014242A1 (en) 2011-01-20
DK1689872T3 (da) 2009-04-27
EP1689872B1 (en) 2009-01-07
ATE504654T1 (de) 2011-04-15
DE602004009743T2 (de) 2008-08-28
DK1845164T3 (da) 2010-09-20
IL199126A (en) 2010-12-30
US7816508B2 (en) 2010-10-19
EA200601043A1 (ru) 2006-10-27
EA012846B1 (ru) 2009-12-30
NZ547405A (en) 2008-06-30
JP2011067219A (ja) 2011-04-07
SG169325A1 (en) 2011-03-30
JP2007512009A (ja) 2007-05-17
AU2004295382A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
ATE523205T1 (de) Prime-boost-impfstoffe gegen malaria
EP1917033A4 (en) VIRUS LIKE PARTICLES AS PARAMYXOVIRUS VACCINES
EA200901060A1 (ru) Новый способ и композиции
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
DK1675956T3 (da) Minimal DNA-sekvens, der virksom som chromatinisolator, og dennes anvendelse til proteinekspression
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
NO20075648L (no) Vaksinesammensetning
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
CO2021007916A2 (es) Ácido ribonucleico (arn) que codifica para una proteína
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
CY1109244T1 (el) Νευρολοιμογονο στελεχος του ιου δυτικου νειλου και εφαρμογες αυτου.
IL164179A0 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
DK0831899T3 (da) Rekombinant koppevirus-calicivirus-præparater og anvendelser
ATE479705T1 (de) Reduzierter slam abhängiger zell eintritt
NO20081541L (no) Ny sjo-lus vaksine
ATE453708T1 (de) Impfstoff gegen west nile virus
NO20005482D0 (no) Rekombinant virus som uttrykker fremmed DNA som koder for Felin CD80, Felin CTLA-4 eller Felin CD86 og anvendelse derav
ATE459643T1 (de) Ee3-proteinfamilie und zugrundeliegende dna- sequenzen
WO2004108939A3 (en) BAV packaging regions and E1 transcriptional control regions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application